Skip to main content

Table 2 Prevalence of mutations in molecular markers of day 0 samples from day 3 positive and negative patients after treatment with artemether-lumefantrine

From: Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar

Gene Mutation n (%) of isolates Pa
Day 3 positive, n = 4 Day 3 negative, n = 26 Total, n = 30
pfk13 K189T 0 (0.0) 3 (11.5) 3 (10.0) 1.000
NN insertion 4 (100.0) 13 (50.0) 17 (56.7) 0.113
pfcrt K76T 4 (100.0) 26 (100.0) 30 (100.0) 1.000
A220S 4 (100.0) 26 (100.0) 30 (100.0) 1.000
Pfmdr1 Y184F 1 (25.0) 6 (23.1) 7 (23.3) 1.000
G968A 0 (0.0) 1 (3.8) 1 (3.3) 1.000
pfdhps S436A 4 (100.0) 20 (76.9) 24 (80.0) 0.557
A437G 4 (100.0) 26 (100.0) 30 (100.0) 1.000
K540E 4 (100.0) 23 (88.5) 27 (90.0) 1.000
A581G 0 (0.0) 1 (3.8) 1 (3.3) 1.000
pfdhfr N51I 4 (100.0) 20 (76.9) 24 (80.0) 0.557
C59R 4 (100.0) 26 (100.0) 30 (100.0) 1.000
S108N 4 (100.0) 26 (100.0) 30 (100.0) 1.000
I164L 3 (75.0) 19 (73.1) 22 (73.3) 1.000
  1. aComparison between the two groups by Fisher’s exact test. Sequences with mixed types were excluded for single mutation analysis